3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Gynecologic
1
Dermatologic
1
Conditions
Melanoma
3
Warts
1
Uveal Melanoma
1
Tuberous Sclerosis
1
Seizures
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphoma, T-Cell
1
Lennox Gastaut Syndrome
1
Hyperthermia
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioblastoma
1
Epilepsies, Myoclonic
1
Brain Neoplasms
1
Interventions
Paclitaxel
69
Bevacizumab
62
Carboplatin
53
pembrolizumab
46
olaparib
32
Specimen Handling
27
Gemcitabine
27
Cyclophosphamide
26
Magnetic Resonance Spectroscopy
24
liposomal doxorubicin
22
Cisplatin
21
niraparib
20
Taxes
18
Nivolumab
18
fludarabine
17
Topotecan
17
Biopsy
17
Doxorubicin
14
Immunoglobulin G
12
Fulvestrant
12
Disulfides
12
Oxaliplatin
10
mirvetuximab soravtansine
9
durvalumab
9
aldesleukin
9
Surveys and Questionnaires
9
Ipilimumab
9
Fluorouracil
9
Blood Specimen Collection
9
cemiplimab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ovarian Neoplasms
×
Solutions
×
1 year
×
Clear all
NCT04752826
2026-02-18
MK-3475-D20
BioInvent International AB
Phase 1/2
Recruiting
176 enrolled